Virology Follow up Study in Subjects Previously Treated With Telaprevir
NCT ID: NCT00916474
Last Updated: 2014-02-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
408 participants
OBSERVATIONAL
2009-06-30
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response
NCT00758043
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
NCT01513941
A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment
NCT00703118
An Exploratory Study of Telaprevir in Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus Infection
NCT00580801
Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection
NCT02452814
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort A
Observational follow-up study to assess long-term response to telaprevir and to evaluate changes in Hepatitis C virus over time
telaprevir
Cohort B
Observational follow-up study to assess long-term response to telaprevir and to evaluate changes in Hepatitis C virus over time
telaprevir
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
telaprevir
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have baseline HCV viral sequencing data available from previous telaprevir study
Exclusion Criteria
* For subjects participating in ongoing studies at the time of enrollment, have more than 90 elapsed days between the database lock or unblinding in the previous telaprevir study and Day 1 in this study
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tibotec Pharmaceutical Limited
INDUSTRY
Vertex Pharmaceuticals Incorporated
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: STUDY_DIRECTOR
Vertex Pharmaceuticals Incorporated
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alabama
Birmingham, Alabama, United States
California
Coronado, California, United States
California
Los Angeles, California, United States
California
San Francisco, California, United States
Colorado
Denver, Colorado, United States
Colorado
Englewood, Colorado, United States
Florida
Gainsville, Florida, United States
Florida
Jacksonville, Florida, United States
Florida
Miami, Florida, United States
Georgia
Altanta, Georgia, United States
Maryland
Baltimore, Maryland, United States
Massachusetts
Boston, Massachusetts, United States
Michigan
Novi, Michigan, United States
Missouri
St Louis, Missouri, United States
New Mexico
Albuquerque, New Mexico, United States
New York
Manhasset, New York, United States
New York
New York, New York, United States
North Carolina
Chapel Hill, North Carolina, United States
North Carolina
Durham, North Carolina, United States
Ohio
Cincinnati, Ohio, United States
South Carolina
Columbia, South Carolina, United States
Texas
Houston, Texas, United States
Texas
San Antonio, Texas, United States
Virginia
Fairfax, Virginia, United States
Virginia
Falls Church, Virginia, United States
Canada
Vancouver, British Columbia, Canada
Canada
Toronto, Ontario, Canada
France
Clichy, , France
France
Marseille, , France
France
Paris, , France
France
Pessac, , France
France
Vandœuvre-lès-Nancy, , France
Germany
Berlin, , Germany
Germany
Cologne, , Germany
Germany
Frankfurt, , Germany
Germany
Freiburg im Breisgau, , Germany
Germany
Hamburg, , Germany
Germany
Hanover, , Germany
Germany
Munich, , Germany
Germany
Wien, , Germany
Puerto Rico
Santurce, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VX08-950-112
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.